Nevertheless, a phase I/II trial study using Navitoclax in combination with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) is recruiting unresectable or metastatic patients with BRAF mutant melanoma (ClinicalTrials.gov, NCT01989585). This evidence concerns the gene MAP2K7 and melanoma.